The First Public Health And Epidemic Prevention Zone Will Be Set Up In The Expo, And The Competition Of New Crown Vaccine In China Market Will Be Accelerated

On November 4, President Xi Jinping pointed out in his keynote speech at the opening ceremony of the third China International Import Expo that China's holding this global trade event on schedule on the premise of ensuring the security of epidemic prevention reflects China's sincere desire to share market opportunities with the world and promote the recovery of the world economy.

"In order to support countries in fighting the epidemic, the Chinese people have unreservedly shared experience with all parties and provided assistance to the international community as far as possible. As of October 20, China has provided anti epidemic assistance to 150 countries and 7 international organizations, exporting more than 179 billion masks, 1.73 billion protective clothing and 543 million test kits, demonstrating China's responsibility." Xi Jinping pointed out.

The reporter of 21st century economic report found that as the first time to enter the Expo after the epidemic situation, a "special zone for public health and epidemic prevention" has been set up in this exhibition area, which will display international advanced public health and epidemic prevention products, technologies, services and hot products that play an important role in the prevention and control of new pneumonia.

Among them, AstraZeneca and Fosun medicine also announced the latest stage progress of their new crown vaccine and the relevant layout in China in the future. For example, AstraZeneca launched clinical trials of new crown vaccine in China in the year, the domestic phase I of new crown vaccine developed by biontech and Fosun medicine entered the data analysis stage, and the clinical phase II bridging trial was actively prepared.

In response to the sudden outbreak of the new epidemic, many countries are actively developing vaccines. At the recent China International Trade in Services Trade Fair (hereinafter referred to as the fair), domestic vaccines also made their debut. "Fighting the epidemic requires global cooperation to maximize solutions," said Ricardo Marek, global executive vice president of Takeda pharmaceuticals. The holding of the Expo and the establishment of the public health and epidemic prevention zone are undoubtedly an important platform for cooperation and exchange. "

First public health and epidemic prevention zone

Compared with the previous two fairs, this year's exhibition area of medical devices and medical care has set up a special public health and epidemic prevention zone.

According to the relevant person in charge of the Expo, the public health and epidemic prevention zone has selected medical equipment and pharmaceutical enterprises that have made outstanding contributions to the fight against the new crown pneumonia epidemic or the related products have been widely used. Among them, nearly 50 enterprises participated, respectively from the United States, Germany, Switzerland and other countries and regions.

According to the understanding of its new drug products in the field of pneumonia prevention. Previously, Milano Furuta, Takeda's global chief strategic officer, told 21st century economic news that Takeda and several major plasma manufacturers in the world started the first covig-19 alliance of plasma derived therapy from May. Plasma derived therapy is made from antibodies produced in the body of the convalescent. These antibodies are first concentrated and then infused to patients.

At the exhibition stand of the public epidemic prevention zone, Lilly also showed its deep cooperation and phased achievements in the field of research and development of new crown expenses. On October 27, Lilly pharmaceutical just released its third quarter 2020 financial report, which showed that both bamlanivimab and baritinib under research had submitted emergency use authorization (EUA) to the food and Drug Administration (FDA). The company estimates that the R & D expenditure of new crown will reach 400 million US dollars in 2020. The increase in R & D expenditure, mainly from R & D investment in the third quarter of 2020, was mainly from R & D investment and related marketing investment of US $1.9 billion.

Fosun health showed products such as Sweden's breas ventilator, negative pressure ambulance, free mobile whole body CT, etc.; Symantec has built a mobile shelter nucleic acid detection laboratory with complete equipment, which is equivalent to domestic P2 and P3 construction standards.

Wang Lei, executive vice president of AstraZeneca global and President of international business and China, said: "in the special period of global epidemic spread, ICIF was held offline as scheduled, which showed the Chinese government's confidence in the anti epidemic achievements and high-level organizational capacity, and further conveyed to the outside world the importance of China's adherence to opening up, strengthening exchanges and cooperation with the world, and sharing the fruits of economic and trade development Want information. All these have given us a firm belief in continuously taking root in the Chinese market and deepening regional strategic development. "

In fact, the establishment of the "public health and epidemic prevention zone" of the fair also reflects the Chinese government's attention to public health and epidemic prevention. In the "suggestions of the CPC Central Committee on formulating the 14th five year plan for national economic and social development and the long-term goals for the year 2035" issued on November 3, it is proposed to reform the disease prevention and control system, and strengthen the functions of monitoring and early warning, risk assessment, epidemiological investigation, testing and emergency response. We should implement the public health responsibility of medical institutions and innovate the coordination mechanism of medical and preventive measures. We will improve the monitoring, early warning and disposal mechanism of public health emergencies, improve the medical treatment, scientific and technological support, and material support systems, and improve the ability to respond to public health emergencies.

Vaccine competition in China

At the Expo, the participating enterprises also brought the news of the new crown vaccine research and development which was the most concerned by the public.

Wang Lei disclosed that the new crown vaccine developed by AstraZeneca and Oxford University will start phase I and phase II clinical trials in China within this year, and it is expected to submit an application for marketing in China after the completion of phase III clinical trials abroad in 2021. The domestic trial samples will be produced and provided by Kangtai biological, and the technical transfer of virus strains is in progress.

In August this year, AstraZeneca announced that it had signed an exclusive licensing cooperation framework agreement with China's vaccine manufacturer Kangtai bio to promote the R & D, production, supply and commercialization of azd1222 vaccine in the mainland of China through technology transfer.

According to the agreement, Kangtai bio, as the technology transferee, will ensure to reach the annual production capacity of at least 100 million doses of new crown vaccine azd1222 by the end of 2020, and expand the design capacity of the vaccine to at least 200 million doses per year by the end of 2021, so as to meet the demand of the Chinese market.

Fosun disclosed to the 21st century economic reporter that the Fosun new crown vaccine developed by Fosun Pharmaceutical Co., Ltd. and Germany's biontech Co., Ltd. is in the domestic clinical phase I, entering the data analysis stage, and the clinical phase II bridging trial is actively preparing.

It is understood that in March this year, Fosun Pharmaceutical cooperated with the world's leading mRNA vaccine R & D enterprise, biontech, to develop and commercialize its exclusive mRNA in China (including Mainland China, Hong Kong, Macao and Taiwan), based on the exclusive mRNA of biontech The technology platform developed vaccine products for covid-19, and made strategic equity investment in biontech.

On July 15, the new bnt162b1 mRNA crown vaccine authorized by biontech was approved by the National Drug Administration. On September 4, all 144 subjects (72 adults and 72 elderly patients) in the phase I clinical trial of bnt162b1 in China had completed both primary and enhanced immunization.

At present, Fosun Pharmaceutical is actively preparing with biontech, and has conducted several rounds of communication with CDE, striving to start the domestic phase II bridging test of bnt162b2 new crown vaccine in China as soon as possible. Fosun said, "we plan to apply for domestic registration based on foreign phase III clinical data and domestic phase II bridging data, which will also shorten the time for bnt162b2 new crown vaccine to be launched in China."

At the recent service trade fair, Chinese enterprises including Beijing Institute of biological products, Wuhan Institute of biological products and Kexing holding Biotechnology Co., Ltd. of Sinopharm Group officially exhibited three new types of inactivated coronavirus vaccines.

On the basis of the 20 million vaccine production capacity of China's joint health and prevention team, Zheng Wei, director of the joint research group of the State Council, said at the end of next year, the joint research group of the State Council will expand the production capacity of new vaccines by the end of this year To ensure the demand of China and other countries in the world.